EI
ALBO

EAM Investors’s Albireo Pharma Inc ALBO Stock Holding History

EAM Investors’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29,151
Closed -$973K – 421
2020
Q3 		$973K Buy
+29,151
New +$849K 0.23% 210
2013
Q3 		– Sell
-8,925
Closed -$1.12M – 377
2013
Q2 		$1.12M Buy
+8,925
New +$929K 0.24% 172

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EAM Investors's ALBO Position: Q4 2020 in Review

EAM Investors sold out of Albireo Pharma Inc (ALBO) in Q4 2020, closing a stake of 29,151 shares — an estimated $973K sold.

EAM Investors first reported a position in ALBO in Q2 2013 and held it in 2 quarters. The position peaked at $1.12M in Q2 2013. 107 funds tracked by Wall St. Rank hold ALBO as of Q4 2020.

  • EAM Investors reported no remaining Albireo Pharma Inc position as of Q4 2020 after selling out during the quarter.
  • EAM Investors sold 29,151 Albireo Pharma Inc shares in Q4 2020, an estimated $973K.
  • EAM Investors first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 2 quarters.
  • EAM Investors's Albireo Pharma Inc position peaked at $1.12M in Q2 2013.
  • 107 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2020.

Based on EAM Investors's 13F filing for Q4 2020, filed 11 Feb 2021.